BeOne Medicines Ltd. (ONC) is a Healthcare stock trading at $346.89 (as of 2026-09-11). Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
BeOne Medicines Ltd. is a global oncology company that focuses on discovering, developing, and commercializing cancer therapies. Its portfolio includes Tevimbra (tislelizumab) and Brukinsa (zanubrutinib), with activities spanning internal R&D and externally sourced development, serving patients across multiple regions and cancer types.
BeOne Medicines develops and commercializes innovative cancer therapies, making money by selling oncology products such as BRUKINSA and Tevimbra.
BeOne's profit engine is commercial oncology product sales, where high gross margins can support ongoing discovery, development, and commercialization.
Business quality (Solid): Solid product economics are visible in gross margin 89% and operating margin 16%, but the current revenue base is overwhelmingly product-led.
| Price | $346.89 |
| DCF Value (model) | $8.60 |
| DCF Upside vs Price | -97.5% |
| Revenue (TTM) | $5.34B |
| Net Margin | 5.4% |
| Return on Equity | 12.7% |
| Debt / Equity | 0.18 |
| Current Ratio | 3.40 |
| Revenue Growth (YoY) | 29.6% |
| EPS Growth (YoY) | 128.6% |
| FCF Growth (YoY) | 187.2% |
| Altman Z-Score | 78.49 (safe) |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Top Institutional Holder | BAKER BROS. ADVISORS LP ($2.51B) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | John V. Oyler |
| Employees | 11,000 |
| Country | US |
| IPO Date | 2016-02-02 |
Data as of 2026-09-11.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.